
    
      Patients are randomized to receive thalidomide or placebo orally at 9 PM the night before
      beginning anti-tuberculosis chemotherapy and continuing nightly for 7 nights. Patients are
      followed for 28 days. Patients are stratified according to HIV status and stage of HIV
      infection.
    
  